Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARTESUNATE vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Severe malaria (parenteral therapy),Uncomplicated malaria (combination therapy with other antimalarials),Off-label: Treatment of chloroquine-resistant falciparum malaria
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Primarily hydrolyzed in the stomach and in plasma by esterases to dihydroartemisinin (DHA), the active metabolite. DHA undergoes glucuronidation via UGT1A9 and UGT2B7.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Artemisinin derivatives: ~93% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Vd approximately 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in severe malaria due to increased capillary permeability.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral: ~40% (range 20-50%) due to first-pass metabolism. Rectal: ~40-60%. IV: 100%.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for Child-Pugh A or B; caution in Child-Pugh C due to limited data.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
2.4 mg/kg IV at 0, 12, 24, and 48 hours; weight-based (minimum 2.4 mg/kg per dose).
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment; use same dosing as adults with monitoring for adverse effects.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
None.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Hemolysis: Cases of delayed hemolytic anemia have been reported, especially in patients with high parasitemia.,Cardiotoxicity: Theoretical risk of QT prolongation with co-administration of other QT-prolonging drugs.,Hypersensitivity: Severe allergic reactions (e.g., anaphylaxis) have occurred.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Hypersensitivity to artesunate, any artemisinin derivative, or any component of the formulation.,Pregnancy: Not recommended in first trimester unless life-threatening; avoid in second/third trimester if safer alternatives available.,Breastfeeding: Safety not established; discontinue breast-feeding or avoid drug.
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
No known significant food interactions. However, avoid grapefruit and grapefruit juice as they may alter drug metabolism (CYP2A6 inhibition). Maintain adequate hydration and nutrition to support recovery.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benefit of treating life-threatening malaria generally outweighs risks, as untreated malaria poses significant fetal risks. However, the drug should be used with caution and only when clearly needed.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Artesunate is excreted into breast milk in small amounts. The M/P ratio is not well-established. While the American Academy of Pediatrics considers artesunate compatible with breastfeeding, caution is advised, especially in nursing preterm or jaundiced infants. The benefits of breastfeeding and the necessity of maternal treatment should be weighed.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
No dose adjustment is required for artesunate during pregnancy based on pharmacokinetic changes. However, intravenous artesunate is the recommended treatment for severe malaria in the second and third trimesters. Oral artesunate may be used for uncomplicated malaria, but caution is advised in the first trimester due to teratogenicity.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Artesunate is the first-line therapy for severe malaria (WHO recommendation). Administer IV or IM; IV dose is 2.4 mg/kg at 0, 12, and 24 hours then daily. Monitor for hypoglycemia and delayed hemolytic anemia (post-artesunate hemolysis). Not recommended for uncomplicated malaria due to risk of resistance. Artesunate is rapidly acting with a short half-life; always combine with a partner drug (e.g., artemether-lumefantrine) for complete cure. Do not use in first trimester of pregnancy unless life-threatening.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take this medication exactly as prescribed; do not stop early even if you feel better.,You may experience temporary side effects such as dizziness, nausea, or fatigue; report any severe reactions.,This drug is used for severe malaria; you will likely be hospitalized for close monitoring.,Watch for signs of low blood sugar (sweating, confusion, rapid heartbeat) and report immediately.,Inform your healthcare provider about all medications you are taking, especially blood thinners or anti-seizure drugs.,Complete the full course of treatment, including any follow-up medications to prevent recurrence.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
"Nicotine, a known inducer of cytochrome P450 (CYP) enzymes, particularly CYP1A2 and possibly CYP2A6, may increase the hepatic metabolism of artesunate to its active metabolite dihydroartemisinin. This enhanced clearance can lead to subtherapeutic plasma concentrations of dihydroartemisinin, reducing the antimalarial efficacy of artesunate and potentially increasing the risk of treatment failure and the development of drug resistance."
"Amiodarone, a potent CYP3A4 and CYP2B6 inhibitor, can significantly reduce the systemic exposure of dihydroartemisinin, the active metabolite of artesunate. This occurs through inhibition of cytochrome P450 enzymes responsible for the conversion of artesunate to its active form, leading to decreased antimalarial efficacy. Clinically, this interaction may result in treatment failure or recrudescence of malaria when artesunate is co-administered with amiodarone."
"The coadministration of buprenorphine, a partial mu-opioid receptor agonist, with artesunate may reduce the systemic exposure of dihydroartemisinin (DHA), the primary active metabolite of artesunate, thereby decreasing antimalarial efficacy. This interaction is believed to occur through buprenorphine-mediated induction of cytochrome P450 (CYP) enzymes responsible for artesunate metabolism, leading to enhanced clearance and subtherapeutic concentration of DHA. Clinically, this could result in delayed parasite clearance and increased risk of treatment failure in malaria patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARTESUNATE vs ARAKODA, answered by our medical review team.
ARTESUNATE is a Antimalarial that works by Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARTESUNATE and ARAKODA depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARTESUNATE is: 2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARTESUNATE and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARTESUNATE is classified as Category C. Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benef. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.